NSCLC, Stage I Clinical Trial
Official title:
Artificial Intelligence Pulmonary Watershed Terrain Navigation System for Lung Nodule Localization and Lung Function Preservation
A method of ICG counterstaining localization under target artery occlusion without cutting，It's a new method of localization of small pulmonary nodules.
1. This technology can replace part of CT puncture-guided positioning, which not only saves CT positioning costs for patients, but also saves time and space resources in CT room; 2. The target artery occlusion technique does not cut off the blood vessels, and the operation is still a wedge resection. Compared with the standard segmentectomy/subsegmentectomy, the steps of cutting off the veins and bronchial tubes are reduced, the operation time is shortened, and the turnover rate is improved. 3. There is less damage to the lung tissue, and the lung function is well preserved. The patients can be discharged in an average of 3 days after the operation, which improves the bed turnover efficiency of the department. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05686434 -
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
|
Phase 2 | |
| Recruiting |
NCT04317534 -
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
|
Phase 2 | |
| Recruiting |
NCT04205552 -
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients
|
Phase 2 | |
| Not yet recruiting |
NCT03446911 -
Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04830826 -
A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
|
||
| Recruiting |
NCT03454685 -
The Role of Microbiota on the Development of Lung Cancer
|
||
| Enrolling by invitation |
NCT06028412 -
Comparison of Segmentectomy and Lobectomy in Small (2 cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study
|
N/A | |
| Recruiting |
NCT03446547 -
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)
|
Phase 2 |